Cancer remains a predominant global health challenge, driven by factors such as genetic susceptibility, environmental exposures, aging populations, and disparities in healthcare access. Despite progress, conventional therapies such as chemotherapy, radiotherapy, and surgery often face limitations, including a lack of specificity, systemic toxicity, and resistance. In this context, nanotechnology offers transformative potential, providing patient-specific, targeted drug delivery systems that can enhance treatment precision and reduce adverse effects. By exploiting the unique properties of nanoscale materials, nanomedicine can improve drug bioavailability, enable controlled release, and support tissue regeneration. Innovations in nanocarriers such as liposomes, dendrimers, and mesoporous silica nanoparticles have shown promise in addressing challenges associated with conventional therapies. Furthermore, advancements in targeted drug delivery, both passive and active, enhance the specificity of treatment, ensuring that drugs reach their intended sites while sparing healthy tissues. The emergence of nanotheranostics, which combine diagnostic and therapeutic capabilities, further drives personalized cancer treatment. Despite these advances, obstacles such as toxicity, scalability, and regulatory hurdles remain. Looking forward, the integration of novel nanocarriers, personalized medicine, and combination therapies holds the potential to revolutionize cancer treatment, ushering in a new era of safer, more effective therapies tailored to individual patient needs.